Skip to main content

Table 2 Clinical outcomes during 1 year of trastuzumab treatment

From: NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab

Clinical outcomes Total group (N = 135), (%) Early-stage (N = 113), (%) Advanced-stage (N = 22), (%)
Cardiac events
 Trastuzumab-induced cardiotoxicity
  Solely LVEF < 45% 1 (1) 0 1 (5)
  Solely absolute LVEF decline > 10% from baseline 29 (21) 26 (23) 3 (14)
  LVEF < 45% and absolute decline > 10% from baseline 15 (11) 12 (11) 3 (14)
  Totala 45 (33) 38 (34) 7 (32)
  Atrial fibrillation 0 0 0
  Myocardial ischemia 0 0 0
  Other cardiac events 0 0 0
  Diastolic dysfunction grade 3 or 4 2 (2) 1 (1) 1 (5)
Postponement of trastuzumab
 Temporarily 6 (4) 6 (5) 0
 Permanent 14 (10) 12 (11) 2 (9)
Death
 Progression disease 4 (3) 2 (2) 2 (9)
  1. Abbreviations: 3DE three-dimensional echocardiography, LVEF left ventricle ejection fraction; aLVEF < 45% and/or absolute LVEF decline > 10%